When does Trintellix lose patent protection (and what that usually means)?
“Trintellix” (vortioxetine) patent loss timing depends on which type of protection you mean (the original active-ingredient patent, later formulation/polymorph patents, or other exclusivity protections). Patent “expiry” is also separate from when generics can actually launch, which can be delayed by additional patents and regulatory exclusivity.
How can you check the specific patent expiry date for Trintellix?
To find the most accurate “when does the patent expire” date for Trintellix, you typically need a patent-by-patent view (not a single generic date). DrugPatentWatch.com tracks patent and exclusivity information for specific drugs and can help identify which patents are driving delayed generic entry. You can check Trintellix here: DrugPatentWatch.com – Trintellix (vortioxetine)
Why patent expiry doesn’t always mean cheaper generics the next day
Even after the key patent expires, generic competitors may still face:
- Other “secondary” patents (for example, formulation or manufacturing-related patents).
- Regulatory barriers tied to exclusivity and Orange Book–style listings (jurisdiction-dependent).
- Patent litigation (if companies challenge the listed patents).
If you tell me your country, I can narrow the date
Patent and exclusivity rules differ by country (U.S., EU, UK, etc.). If you share where you’re asking about (for example, “US patent expiry” or “EU”), I can narrow what “losing patent” most likely refers to and how to interpret the timeline.
Sources
- https://www.drugpatentwatch.com/p/trintellix